ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy

Spencer, Kevin; Cowans, Nicholas J.

doi:10.1080/14767050701483389

Cited by 33 publications

(21 citation statements)

References 39 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following correction for gestational age and maternal factors, the current study was unable to support this. Our data support findings from previous studies where ADAM-12 levels have been shown to be positively correlated with PAPP-A [19, 32,40] . In addition, we have also shown ADAM-12 and PP13 levels to correlate.…”

Section: Discussionsupporting

confidence: 83%

Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes

Matwejew

Cowans²,

Stamatopoulou³

et al. 2010

Fetal Diagn Ther

View full text Add to dashboard Cite

Objective: To investigate first-trimester ADAM-12 levels in pregnancies which later develop hypertensive and growth complications. Methods: First-trimester serum samples (11⁺⁰ to 13⁺⁶ weeks) were retrieved from frozen storage. 47 samples with at least one of the following adverse outcomes: pre-eclampsia (PE), small for gestational age, HELLP syndrome and gestational hypertension were analysed and 452 controls matched to the cases by gestational age and length of storage were analysed. ADAM-12 levels were measured by the automated AutoDELFIA immunoassay platform. Results: ADAM-12 was found to increase with gestational age (11⁺⁰ to 13⁺⁶ weeks) and decrease with increasing maternal weight and in women who smoked. After correction, ADAM-12 median multiples of the median were increased in cases with HELLP syndrome, all PE and PE only. Conclusion: The increased first-trimester levels of ADAM-12 in PE and HELLP are in contrast with previous findings. The usefulness of ADAM-12 as a marker for adverse outcomes is still unclear.

show abstract

Section: Discussionsupporting

confidence: 83%

Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes

Matwejew

Cowans²,

Stamatopoulou³

et al. 2010

Fetal Diagn Ther

View full text Add to dashboard Cite

show abstract

“…For example, ADAM12 (a disintegrin and metalloprotease 12) shows evidence of positive selection on the primate stem lineage ( ω =8.155, p=0.00691, PSS%=0.83%). ADAM12 mediates syncytiotrophoblastic shedding of oxytocinase [49] and its reduced maternal serum concentrations were reported in early pregnancies that are complicated with fetal trisomies 18 and 21 [50], and in pregnant women who subsequently developed preeclampsia [51]. FN1 (fibroncetin 1) shows evidence for positive selection on the Euarchontoglires stem lineage ( ω =170.096, p=0.0225, PSS%=0.06%).…”

Section: Discussionmentioning

confidence: 99%

Adaptive history of single copy genes highly expressed in the term human placenta

Hou¹,

Romero²,

Uddin³

et al. 2009

Genomics

View full text Add to dashboard Cite

The chorioallantoic placenta is a shared derived feature of “placental” mammals essential for the success of eutherian reproduction. Identifying the genes involved in the emergence of the placenta may provide clues for understanding the biology of this organ. Here we identify among 4960 single copy genes in mammals, 222 that show high expression levels in human placentas at term. Further, we present evidence that 94 of these 222 genes evolved adaptively during human evolutionary history since the time of the last common ancestor of eutherian mammals. Remarkably, the majority of positive selection occurred on the eutherian stem lineage suggesting that ancient adaptations have been retained in the human placenta. Of these positively selected genes, 28 have been shown to play a role in human pregnancy and placental biology, and at least 26 have important pregnancy-related phenotypes in mice. Adaptations in genes highly expressed in human placenta are attractive candidates for functional and clinical studies.

show abstract

“…ADAM12 has been studied as a first trimester marker for predicting pre-eclampsia [8]–[10], aneuploidy [8], [10]–[15] and small-for-gestational age fetuses [16], [17]. A clear biological explanation for the decreased level of ADAM12 in EPs does not exist; however, the predominant theory involving impaired placentation could account for ADAM12 playing an important role in the growth and function of the placenta [8].…”

Section: Discussionmentioning

confidence: 99%

Maternal Serum Disintegrin and Metalloprotease Protein-12 in Early Pregnancy as a Potential Marker of Adverse Pregnancy Outcomes

Yang

Guo

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

ObjectivesThe aim of this study was to determine whether the concentration of disintegrin and metalloprotease protein12 (ADAM12) in first trimester maternal serum can be used as a marker for first-trimester complete spontaneous abortions, missed abortions, ectopic pregnancies and hydatidiform moles.MethodsThe maternal serum concentrations of ADAM12 were measured in the range of 5–9+6 weeks of gestation using an automated AutoDelfia immunoassay platform in 9 cases of complete spontaneous abortion, 27 cases of missed abortions, 56 cases of ectopic pregnancies, 12 cases of hydatidiform moles, and 100 controls. Logistic regression analysis was used to determine significant factors for predicting adverse pregnancy outcomes in early pregnancy. Screening performance was assessed using receiver operating characteristic curves.ResultsTwo hundred and four women were enrolled in the study. In the control group, the level of ADAM12 increased with gestational age. The median ADAM12 levels in the spontaneous abortion (0.430 MoM), ectopic pregnancy (0.460 MoM) and hydatidiform mole (0.037 MoM) groups were lower than that in the control group, while the median ADAM12 level in the missed abortion group (1.062 MoM) was not significant from the controls (1.002 MoM). Logistic regression analysis demonstrated that the level of ADAM12 in maternal serum facilitated the detection of ectopic pregnancies (OR = 0.909; 95% CI = 0.841∼0.982) and complete spontaneous abortion (OR = 0.863; 95% CI = 0.787∼0.946).ConclusionsIn complete spontaneous abortion and ectopic pregnancy, ADAM12 maintained at low levels in early pregnancies, and there were significant differences compared to normal pregnancies. ADAM12 is a promising marker for the diagnosis of complete spontaneous abortion and ectopic pregnancy in symptomatic women, and under certain conditions, ADAM12 can diagnose ectopic pregnancy and spontaneous abortion before an ultrasonographic detection of the conditions.

show abstract

ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy

Abstract: ADAM12 may be a useful addition to early screening for trisomy 18 alongside other chromosomal anomalies, particularly if biochemical screening can occur before 10 weeks.

Cited by 33 publications

References 39 publications

Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes

Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes

Adaptive history of single copy genes highly expressed in the term human placenta

Maternal Serum Disintegrin and Metalloprotease Protein-12 in Early Pregnancy as a Potential Marker of Adverse Pregnancy Outcomes

Contact Info

Product

Resources

About